GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenith Capital Corporation (TSXV:ZENI.P) » Definitions » Profitability Rank

Zenith Capital (TSXV:ZENI.P) Profitability Rank : 1 (As of Jan. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Zenith Capital Profitability Rank?

Zenith Capital has the Profitability Rank of 1. It has had trouble to make a profit.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Zenith Capital's Operating Margin % for the quarter that ended in Jan. 2024 was %. As of today, Zenith Capital's Piotroski F-Score is 2.


Competitive Comparison of Zenith Capital's Profitability Rank

For the Biotechnology subindustry, Zenith Capital's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zenith Capital's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zenith Capital's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Zenith Capital's Profitability Rank falls into.



Zenith Capital Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Zenith Capital has the Profitability Rank of 1. It has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Zenith Capital's Operating Margin % for the quarter that ended in Jan. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Jan. 2024 ) / Revenue (Q: Jan. 2024 )
=-2.558 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

Warning Sign:

Piotroski F-Score of 2 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Zenith Capital has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


Zenith Capital Profitability Rank Related Terms

Thank you for viewing the detailed overview of Zenith Capital's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Zenith Capital (TSXV:ZENI.P) Business Description

Traded in Other Exchanges
N/A
Address
2475 Queens Avenue, West Vancouver, BC, CAN, V7V 2Y9
Zenith Capital Corporation is a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics for the treatment of cancer and other disorders with significant unmet medical needs. The company is developing various novel combinations of BET inhibitors with other targeted agents. The lead compound, ZEN-3694, is in clinical development for mCRPC in combination with androgen receptor inhibitor, XTANDI, with Astellas and Newsoara as collaborators; triple-negative breast cancer in combination with the PARP inhibitor TALZENNA with Pfizer as a collaborator; androgen receptor independent mCRPC in combination with immune checkpoint inhibitor KEYTRUDA and XTANDI with University of California, San Francisco as a collaborator.

Zenith Capital (TSXV:ZENI.P) Headlines

No Headlines